How to Conduct Sensitivity Analyses for Missing Data Assumptions in Clinical Trials

Missing data in clinical trials introduces uncertainty that can threaten the reliability of results. While primary analyses often assume missing at random (MAR), real-world data may violate this assumption. Sensitivity analyses are therefore essential to evaluate how robust your conclusions are under different missing data mechanisms, particularly Missing Not at Random (MNAR).

This tutorial explores the methods used for sensitivity analyses, including delta-adjusted multiple imputation, tipping point analysis, and pattern-mixture models. We’ll also touch on regulatory expectations and best practices to ensure your study meets standards set by agencies like the USFDA and EMA.

Why Sensitivity Analyses Are Critical

Primary imputation methods (e.g., MMRM, multiple imputation) often rely on MAR. But if data are Missing Not at Random (MNAR), these methods may yield biased results. Sensitivity analyses explore alternative assumptions to assess:

• The robustness of the treatment effect
• The direction and magnitude of bias
• The clinical significance of different assumptions

These analyses should be pre-specified in the Statistical Analysis Plan (SAP) and reported in the Clinical Study Report (CSR), as emphasized in GMP documentation.

Common Sensitivity Analysis Methods for Missing Data

1. Delta-Adjusted Multiple Imputation

This approach modifies imputed values by applying a delta shift, simulating different degrees of missing data bias. It allows trialists to explore the impact of worse (or better) outcomes among those with missing data.

How It Works:

• Standard multiple imputation is performed
• A delta value is added (or subtracted) from imputed outcomes
• Analysis is repeated to observe impact on treatment effect

Example: In a depression trial, if missing values are suspected to come from patients with worse outcomes, a delta of -2 is applied to imputed depression scores.

2. Tipping Point Analysis

This technique identifies the point at which the trial conclusion would change (i.e., lose statistical significance) under worsening assumptions for missing data.

Steps:

1. Systematically vary imputed values for missing data
2. Recalculate treatment effects across scenarios
3. Identify the “tipping point” where the conclusion shifts

This method is especially valuable in regulatory discussions where reviewers request a range of plausible scenarios before accepting efficacy claims.

3. Pattern-Mixture Models (PMM)

PMMs group data by missing data patterns (e.g., completers, early dropouts) and model each separately. They allow for explicit modeling of MNAR mechanisms by assigning different outcome distributions to different patterns.

Advantages:

• Can accommodate both MAR and MNAR scenarios
• Provides flexibility in modeling dropout effects
• Supported by regulators when assumptions are transparently defined

4. Selection Models

These models jointly model the outcome and the missingness mechanism. They require strong assumptions about how dropout depends on unobserved data.

Limitations:

• Complex to implement
• Highly sensitive to model misspecification

Though powerful, selection models are often used in conjunction with simpler methods like delta-adjusted MI to provide a full spectrum of analyses.

When and How to Apply Sensitivity Analyses

When:

• When primary analysis assumes MAR but MNAR is plausible
• When dropout rates exceed 10% and relate to outcome severity
• When regulators request additional robustness evidence

How:

1. Specify methods and rationale in the SAP
2. Use validated tools (e.g., SAS, R) for multiple imputation with delta shifts
3. Present results with confidence intervals and direction of change
4. Document any model assumptions clearly

These practices are outlined in clinical trial SOPs and should align with ICH E9(R1) guidelines on estimands and intercurrent events.

Regulatory Perspectives on Sensitivity Analyses

Agencies like the EMA and CDSCO recommend the inclusion of sensitivity analyses under different assumptions. These analyses:

• Strengthen confidence in trial conclusions
• Demonstrate robustness of efficacy or safety findings
• Support labeling decisions in case of high attrition

Regulators particularly value tipping point analysis for its transparency in evaluating how results depend on missing data assumptions.

Best Practices for Sensitivity Analyses

• Plan analyses during study design—not post hoc
• Use multiple methods to triangulate findings
• Report both adjusted and unadjusted results
• Involve biostatisticians early in protocol development
• Interpret findings with both statistical and clinical context

Practical Example

In a diabetes trial with 15% dropout, primary analysis used MMRM under MAR. Sensitivity analysis using delta-adjusted MI applied values from -0.5 to -2.5 mmol/L for missing HbA1c values. At a delta of -1.5, the treatment effect remained statistically significant. At -2.0, the p-value crossed 0.05. The tipping point was thus delta = -2.0, which was deemed unlikely based on observed dropout characteristics.

This demonstrated that conclusions were robust under realistic assumptions, a crucial component of the sponsor’s submission dossier.

Conclusion

Sensitivity analyses for missing data are no longer optional—they are essential for regulatory acceptance and scientific credibility. By exploring alternative assumptions through techniques like delta adjustment, tipping point analysis, and pattern-mixture models, researchers can demonstrate the reliability of their conclusions despite missing data. A well-planned sensitivity analysis strategy ensures that your clinical trial meets modern regulatory expectations and supports confident decision-making in drug development.